Please assess the completion status of the following clinical trial:

Trial Title: A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (male/ female) of specific age groups (2-6 years, 7-11 years, 12-17 years) who are scheduled to undergo Gadolinium (Gd)-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).~Exclusion Criteria:~* Clinically unstable patients (e.g. intensive care unit)~* Renal insufficiency~* Patients undergoing a relevant change in chemotherapy \</= 48 hours prior to and up to 24 hours after the administration of Gadovist.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years (Type: EXPERIMENTAL): Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
- Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years (Type: EXPERIMENTAL): Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
- Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years (Type: EXPERIMENTAL): Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
- Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years (Type: EXPERIMENTAL): Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection

Based on this trial design, predict the completion outcome and termination type (if applicable).